Population pharmacokinetics of colistin methanesulfonate and colistin in critically ill patients with acute renal failure requiring intermittent hemodialysis

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 3, 2016, Pages 1788-1793

  Jacobs, M ^a,b   Gregoire, N ^a,b   Megarbane B ^c   Gobin, P ^a,d   Balayn, D ^a,d   Marchand, S ^a,b,d   Mimoz, O ^a,b,d   Couet, W ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN; CREATININE; ANTIINFECTIVE AGENT; COLISTINMETHANESULFONIC ACID;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DRUG CLEARANCE; FEMALE; HEMODIALYSIS; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; LUNG INFECTION; MAINTENANCE DRUG DOSE; MALE; MIDDLE AGED; MONTE CARLO METHOD; PRIORITY JOURNAL; PROTEIN BINDING; RENAL CLEARANCE; REPEATED DRUG DOSE; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; STEADY STATE; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; CRITICAL ILLNESS; DRUG ADMINISTRATION; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; LUNG; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOLOGY; RESPIRATORY TRACT INFECTIONS; VERY ELDERLY;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RENAL DIALYSIS; RESPIRATORY TRACT INFECTIONS;

EID: 84960145056     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01868-15     Document Type: Article

References (21)

1. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: The re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect Dis 6:589-601. http://dx.doi.org/10.1016/S1473-3099(06)70580-1.
2. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2015. Framework for optimisation of the clinical use of colistin and polymyxin B: The Prato polymyxin consensus. Lancet Infect Dis 15:225-234. http://dx.doi.org/10.1016/S1473-3099(14)70850-3.
3. Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. 2013. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: The study, the patient, the bug or the drug? J Infect 66:401-414. http://dx.doi.org/10.1016/j.jinf.2012.10.028.
4. Couet W, Gregoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O. 2011. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 89:875-879. http://dx.doi.org/10 .1038/clpt.2011.48.
5. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284-3294. http://dx.doi.org/10.1128/AAC.01733-10.
6. Gregoire N, Mimoz O, Megarbane B, Comets E, Chatelier D, Lasocki S, Gauzit R, Balayn D, Gobin P, Marchand S, Couet W. 2014. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob Agents Chemother 58: 7324-7330. http://dx.doi.org/10.1128/AAC.03508-14.
7. Marchand S, Frat JP, Petitpas F, Lemaitre F, Gobin P, Robert R, Mimoz O, Couet W. 2010. Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 65:1836-1837. http://dx.doi.org/10.1093/jac/dkq185.
8. Jitmuang A, Nation RL, Koomanachai P, Chen G, Lee HJ, Wasuwattakul S, Sritippayawan S, Li J, Thamlikitkul V, Landersdorfer CB. 2015. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: Implications for dosing. J Antimicrob Chemother 70:1804-1811.
9. Luque S, Sorli L, Li J, Collado S, Barbosa F, Berenguer N, Horcajada JP, Grau S. 2014. Effective removal of colistin methanesulphonate and formed colistin during intermittent haemodialysis in a patient infected by polymyxin-only-susceptible Pseudomonas aeruginosa. J Chemother 26: 122-124. http://dx.doi.org/10.1179/1973947813Y.0000000104.
10. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gramnegative bacteria. Antimicrob Agents Chemother 53:3430-3436. http://dx.doi.org/10.1128/AAC.01361-08.
11. Gobin P, Lemaitre F, Marchand S, Couet W, Olivier JC. 2010. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography tandem mass spectrometry. Antimicrob Agents Chemother 54:1941-1948. http://dx.doi.org/10.1128/AAC.01367-09.
12. Boisson M, Jacobs M, Gregoire N, Gobin P, Marchand S, Couet W, Mimoz O. 2014. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother 58:7331-7339. http://dx.doi.org/10.1128/AAC.03510-14.
13. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481-504. http://dx.doi .org/10.1023/A:1012299115260.
14. Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL. 2015. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: Smaller response in lung infection. J Antimicrob Chemother 70:3291-3297.
15. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE. 2012. Application of a loading dose of colistin methanesulfonate (CMS) in critically ill patients: Population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56:4241-4249. http://dx.doi.org/10.1128/AAC.06426-11.
16. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2014. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis 58:139-141. http://dx.doi.org/10.1093/cid/cit680.
17. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. 2008. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 52:3047-3051. http://dx.doi.org/10.1128/AAC.00103-08.
18. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:1953-1958. http://dx.doi.org/10.1128/AAC .00035-06.
19. He H, Li JC, Nation RL, Jacob J, Chen G, Lee HJ, Tsuji BT, Thompson PE, Roberts K, Velkov T, Li J. 2013. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J Antimicrob Chemother 68:2311-2317.
20. Azad MA, Huang JX, Cooper MA, Roberts KD, Thompson PE, Nation RL, Li J, Velkov T. 2012. Structure-activity relationships for the binding of polymyxins with human alpha-1-acid glycoprotein. Biochem Pharmacol 84:278-291. http://dx.doi.org/10.1016/j.bcp.2012.05.004.
21. Blot SI, Pea F, Lipman J. 2014. The effect of pathophysiology on pharmacokinetics in the critically ill patient- concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 77:3-11. http://dx.doi.org/10.1016/j.addr.2014.07.006.